Skip to main content
Skip to navigation
Skip to search
Login icon
Login or register
Logged in
Login icon
Log out
Search
Disease areas
Acromegaly
Opioid dependence
Congresses
Publications
Science
R&D pipeline
Technology
Resources
Acromegaly
Opioid Dependence
OBAP Study Webinar 2025
Contact
ENEA 2025
Poster Access
CAM2029 octreotide subcutaneous depot maintains control of IGF-I and symptoms of acromegaly across a 4-week dosing interval and for intervals greater than 28 days: data from the ACROINNOVA 1 trial
Long-term and sustained biochemical control of acromegaly and improved quality of life with CAM2029 octreotide subcutaneous depot: final analysis of the core phase of ACROINNOVA 2
